Irritable bowel syndrome (IBS) is characterised by abdominal pain and an erratic bowel habit, which depending on the definition used affects 5–10% of the population. As a typical complex disease, it is likely that the condition will develop when a genetically susceptible individual is exposed to an appropriate environment stimulus. This bio-psycho-social model assumes that there is no one cause of IBS, but rather that it is the product of complex interactions between host and environment. Host factors include gender, age and psychological characteristics, while environmental factors include psychosocial stressors, gastrointestinal infections, antibiotics and food.

Keywords:
Gastrointestinal infection, Irritable bowel syndrome, genetic factors, Irritable bowel syndrome, lifestyle, Impaired descending antinociception, females, Postinfectious irritable bowel syndrome, Psychological comorbidity
1.
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008;40:955–962.
2.
Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA: Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799–804.
3.
Levy RL, Whitehead WE, Von Korff MR, Feld AD: Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000;95:451–456.
4.
Vergne DE, Nemeroff CB: The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression. Curr Psychiatry Rep 2006;8:452–457.
5.
Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK: Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502–1513.
6.
Jones R, Latinovic R, Charlton J, Gulliford M: Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. Aliment Pharmacol Ther 2006;24:879–886.
7.
Nicholl BI, Halder SL, Macfarlane GJ, Thompson DG, O’Brien S, Musleh M, McBeth J: Psychosocial risk markers for new onset irritable bowel syndrome – results of a large prospective population-based study. Pain 2008;137:147–155.
8.
Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P: Irritable bowel syndrome: a 10-year natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008;103:1229–1239.
9.
Dunlop SP, Jenkins D, Spiller RC: Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol 2004;16:1011–1015.
10.
Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G: Mucosal immune activation in irritable bowel syndrome: gender dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392–400.
11.
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–627.
12.
Isong U, Gansky SA, Plesh O: Temporomandibular joint and muscle disorder-type pain in US adults: the National Health Interview Survey. J Orofac Pain 2008;22:317–322.
13.
McBeth J, Macfarlane GJ, Benjamin S, Silman AJ: Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum 2001;44:940–946.
14.
Clemens JQ, Meenan RT, O’Keeffe Rosetti MC, Brown SO, Gao SY, Calhoun EA: Prevalence of interstitial cystitis symptoms in a managed care population. J Urol 2005;174:576–580.
15.
Matías-Guiu J, Porta-Etessam J, Mateos V, Díaz-Insa S, Lopez-Gil A, Fernández C: One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia 2010 (in press).
16.
Evengard B, Jacks A, Pedersen NL, Sullivan PF: The epidemiology of chronic fatigue in the Swedish Twin Registry. Psychol Med 2005;35:1317–1326.
17.
Nimnuan C, Hotopf M, Wessely S: Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res 2001;51:361–367.
18.
Halder SL, Locke GR III, Schleck CD, Zinsmeister AR, Melton LJ III, Talley NJ: Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007;133:799–807.
19.
Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III: Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642–649.
20.
Zhou Q, Fillingim RB, Riley JL III, Verne GN: Thermal hypersensitivity in a subset of irritable bowel syndrome patients. World J Gastroenterol 2009;15:3254–3260.
21.
Wiesenfeld-Hallin Z, Xu XJ, Crawley JN, Hokfelt T: Galanin and spinal nociceptive mechanisms: recent results from transgenic and knock-out models. Neuropeptides 2005;39:207–210.
22.
Paulson PE, Minoshima S, Morrow TJ, Casey KL: Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans. Pain 1998;76:223–229.
23.
Zhuo M, Gebhart GF: Facilitation and attenuation of a visceral nociceptive reflex from the rostroventral medulla in the rat. Gastroenterology 2002;122:1007–1019.
24.
Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A: Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004;53:1595–1601.
25.
Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R: Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004;53:1465–1470.
26.
Krzanowska EK, Bodnar RJ: Analysis of sex and gonadectomy differences in β-endorphin antinociception elicited from the ventrolateral periaqueductal gray in rats. Eur J Pharmacol 2000;392:157–161.
27.
Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS: Mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci 2002;22:5100–5107.
28.
Creed F, Craig T, Farmer R: Functional abdominal pain, psychiatric illness, and life events. Gut 1988;29:235–242.
29.
Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400–406.
30.
Rodriguez LA, Ruigomez A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565–566.
31.
Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS, Hudson MJ, Roderick PJ: Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. BMJ 1999;318:1046–1050.
32.
Spiller R, Garsed K: Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979–1988.
33.
Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM: Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445–450.
34.
McKendrick MW, Read NW: Irritable bowel syndrome – post Salmonella infection. J Infect 1994;29:1–3.
35.
Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779–782.
36.
Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651–1659.
37.
Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC: Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001;184:606–609.
38.
Parry SD, Barton JR, Welfare MR: Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol 2005;17:1071–1075.
39.
Balamurugan R, Janardhan HP, George S, Raghava MV, Muliyil J, Ramakrishna BS: Molecular studies of fecal anaerobic commensal bacteria in acute diarrhea in children. J Pediatr Gastroenterol Nutr 2008;46:514–519.
40.
Barbara G, Stanghellini V, Berti-Ceroni C, De Giorgio R, Salvioli B, Corradi F, Cremon C, Corinaldesi R: Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. Aliment Pharmacol Ther 2000;14:1127–1131.
41.
Stermer E, Lubezky A, Potasman I, Paster E, Lavy A: Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006;43:898–901.
42.
Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804–811.
43.
Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM: Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004;20:1317–1322.
44.
Coleman NS, Foley S, Dunlop SP, Wheatcroft J, Blackshaw E, Perkins AC, Singh G, Marsden CA, Holmes GK, Spiller RC: Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006;4:874–881.
45.
Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, Grundy D: Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol 2008;586:4517–4530.
46.
Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM: Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–526.
47.
Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096–1101.
48.
Foley KF, Pantano C, Ciolino A, Mawe GM: IFN-γ and TNF-α decrease serotonin transporter function and expression in Caco2 cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G779–G784.
49.
Thompson WG, Heaton KW, Smyth GT, Smyth C: Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78–82.
50.
Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH: Role of mast cells in chronic stress-induced colonic epithelial barrier dysfunction in the rat. Gut 2001;48:630–636.
51.
Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.
52.
Barbara G, Wang B, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R: Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26–37.
53.
Buhner S, Li Q, Vignali S, Barbara G, De GR, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Schemann M: Activation of human enteric neurons by supernatants of colonic biopsies from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425–1434.
54.
Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR: Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203–209.
55.
Santos J, Saperas E, Nogueiras C, Mourelle M, Antolin M, Cadahia A, Malagelada JR: Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998;114:640–648.
56.
Wallon C, Yang PC, Keita AV, Ericson AC, McKay DM, Sherman PM, Perdue MH, Soderholm JD: Corticotropin-releasing hormone regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50–58.
57.
Ragnarsson G, Bodemar G: Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome. Patients’ description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998;10:415–421.
58.
Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H: Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996;31:581–589.
59.
Small PK, Loudon MA, Hau CM, Noor N, Campbell FC: Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997;32:39–47.
60.
Hoad CL, Marciani L, Foley S, Totman JJ, Wright J, Bush D, Cox EF, Campbell E, Spiller RC, Gowland PA: Non-invasive quantification of small bowel water content by MRI: a validation study. Phys Med Biol 2007;52:6909–6922.
61.
Marciani L, Cox EF, Hoad CL, Pritchard S, Totman JJ, Foley S, Mistry A, Evans S, Gowland PA, Spiller RC: Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010;138:469–77, 477.
62.
Tache Y, Martinez V, Wang L, Million M: CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004;141:1321–1330.
63.
Fukudo S, Nomura T, Hongo M: Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42:845–849.
64.
Garsed K, Marciani L, Roberts E, Thongborisute W, Pritchard S, Costigan C, Hoad CL, Gowland PA, Spiller RC: Stress reduces small bowel water content in healthy volunteers. Neurogastroenterol Motil 2010;22: Suppl; A70.
65.
Cann PA, Read NW, Cammack J, Childs H, Holden S, Kashman R, Longmore J, Nix S, Simms N, Swallow K, Weller J: Psychological stress and the passage of a standard meal through the stomach and small intestine in man. Gut 1983;24:236–240.
66.
Ditto B, Miller SB, Barr RG: A one-hour active coping stressor reduces small bowel transit time in healthy young adults. Psychosom Med 1998;60:7–10.
67.
Gorard DA, Gomborone JE, Libby GW, Farthing MJ: Intestinal transit in anxiety and depression. Gut 1996;39:551–555.
68.
Ladas S, Papanikos J, Arapakis G: Lactose malabsorption in Greek adults: correlation of small bowel transit time with the severity of lactose intolerance. Gut 1982;23:968–973.
69.
Shepherd SJ, Parker FC, Muir JG, Gibson PR: Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6:765–771.
70.
Shepherd SJ, Gibson PR: Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc 2006;106:1631–1639.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.